Project Grant R03HL187226
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $225K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90027, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded the Massachusetts General Hospital's Research Management Division $842,536 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanisms linking gestational diabetes mellitus (GDM) to increased coronary artery disease risk in women. The research integrates longitudinal electronic health records data spanning approximately 30 years postpartum for more than 208,000 women with GDM...
- The National Heart, Lung, and Blood Institute awarded $249,000 to The University of Texas Southwestern Medical Center on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund investigator-initiated research on fetal congenital heart disease and placental inflammation. Dr. Rachel Leon, an assistant professor in the Division of Neonatal-Perinatal Medicine at UT Southwestern and current NHLBI K23 awardee, will use advanced MRI techniques to investigate the influence...
- The National Heart, Lung, and Blood Institute awarded the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $161,500 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support planning activities for a future multisite cluster randomized trial on hypertensive disorders of pregnancy prevention in safety-net clinics. The award funds a preparation phase to evaluate the feasibility and acceptability of implementation intervention...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $531,794 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of microRNA-98-5p (mir98) in myocardial ischemia-reperfusion injury during late pregnancy. The research addresses the mechanism underlying increased myocardial infarct size in late-pregnancy rats compared to non-pregnant rats. Prior work from the recipient's laboratory demonstrated a...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital Corporation (doing business as Boston Children's Hospital) $825,533 for Project Grant R01HL182745 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The project investigates glycorna-based control of angiogenesis through heparan sulfate binding growth factors. Research focuses on how vascular endothelial growth factor (VEGF-A) orchestrates vascular and cardiac development by binding...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $783,885 for Project Grant R01HL181589 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research on the role of NTRK2 isoforms in alveolar injury and repair related to bronchopulmonary dysplasia (BPD), a chronic lung disease affecting approximately 10,000 premature infants annually in the United States. The research employs multiomic profiling...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $2,401,048 for Project Grant R01HL184086 on September 1, 2026 under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds GO MOMS PREDICT, a prospective study that develops and tests pregnancy-based cardiovascular disease risk assessment models to predict cardiovascular outcomes five years after delivery. The study leverages an existing...
- The National Heart, Lung, and Blood Institute awarded the University of Miami $345,375 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of gasdermin-D in neonatal hyperoxia-induced vascular remodeling and cardiac dysfunction. The project grant (R03HL183267) runs through February 28, 2028, with work performed in Miami, Florida. The research targets mechanisms by which oxygen therapy in preterm infants—necessary to ensure adequate oxygen...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $1,818,088 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how postnatal hypoxemia—reduced blood oxygen levels present in cyanotic congenital heart disease—impacts cardiac maturation and surgical recovery outcomes in pediatric patients. The project will examine the interaction between hypoxemia, myocardial immaturity, and postoperative complications through...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $174,621 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance imaging (CMR) techniques for monitoring congenital heart disease using ultra-low field (ULF) MRI systems. The recipient will adapt CMR to an inexpensive, unshielded, open-geometry ULF MRI system and apply machine learning techniques to mitigate hardware limitations and...